Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Feb;66(2):143-50.
doi: 10.1136/ard.2006.061002. Epub 2006 Oct 26.

Consensus statement on the use of rituximab in patients with rheumatoid arthritis

J S Smolen  1 , E C Keystone, P Emery, F C Breedveld, N Betteridge, G R Burmester, M Dougados, G Ferraccioli, U Jaeger, L Klareskog, T K Kvien, E Martin-Mola, K Pavelka; Working Group on the Rituximab Consensus Statement
Affiliations

Consensus statement on the use of rituximab in patients with rheumatoid arthritis

J S Smolen et al. Ann Rheum Dis. 2007 Feb.

Abstract

A large number of experts experienced in the treatment of rheumatoid arthritis were involved in formulating a consensus statement on the use of B cell-targeted treatment with rituximab in patients with rheumatoid arthritis. The statement was supported by data from randomised controlled clinical trials and the substantial literature on oncology. The statement underwent three rounds of discussions until its ultimate formulation. It should guide clinicians in the use of this newly approved biological agent in treating patients with rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The views expressed in this guidance document including the final recommendations were not influenced by the sponsor and no representative of the sponsor was present in any of the discussion sessions. However, the guidance document was developed with the help of an unrestricted educational grant and all participants except the patient representative have been active on advisory boards or participated in clinical trials by the sponsor.

References

    1. Drossaers‐Bakker K W, de Buck M, van Zeben D, Zwinderman A H, Breedveld F C, Hazes J M. Long‐term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999421854–1860. - PubMed
    1. Aletaha D, Smolen J S. The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum Dis Clin North Am 2006329–44. - PubMed
    1. Emery P. Treatment of rheumatoid arthritis. BMJ 2006332152–155. - PMC - PubMed
    1. Combe B, Landewe R, Lukas C, Bolosiu H D, Breedveld F C, Dougados M.et al EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006. Published Online First: 5 January 2006, doi: 10.1136/ard.2005.044354 - PMC - PubMed
    1. Furst D E, Breedveld F C, Kalden J R, Smolen J S, Burmester G R, Bijlsma J W.et al Updated consensus statement on biological agents, specifically tumour necrosis factor (alpha) (TNF(alpha)) blocking agents and interleukin‐1 receptor antagonist (IL‐1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 200564iv2–NaN14. - PMC - PubMed

Publication types

MeSH terms